Als erstes Land weltweit hat #Japan das Medikament Hibsago (Wirkstoff: #Bepirovirsen) gegen chronische #HepatitisB zugelassen. In fast 20% aller Fälle konnte das Medikament in Phase-III-Studien eine funktionelle Heilung erreichen (verglichen mit etwa 1% bei den bisher verfügbaren Medikamenten). /2

GSK: Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B

bit.ly/4wJE1zA

#Japan hat #GSKs #Hibsago für chronische #HepatitisB und #Takedas #Orzeyful für #Narkolepsie Typ 1 zugelassen www.ipharmacenter.com/post/japan-a...
#Japan #Nachrichten #Medien #Pharma #Gesundheit #Pharmazeutik

#日本 已批准 #GSK 用于治疗慢性 #乙肝 的 #Hibsago 以及 #武田 用于治疗1型 #发作性睡病 的 #Orzeyful
www.ipharmacenter.com/post/japan-a...
#日本 #新闻 #媒体 #医药 #医疗健康 #生物医药

#日本 が慢性 #B型肝炎 治療薬として #GSK の #ヒブサゴ （#Hibsago）、#ナルコレプシー 1型治療薬として #武田薬品 の #オーゼイフル （#Orzeyful）を承認
www.ipharmacenter.com/post/japan-a...
#日本 #ニュース #メディア #製薬 #ヘルスケア

3️⃣ Ein Zulassungsantrag für das Medikament Hibsago (Wirkstoff #Bepirovirsen) gegen chronische #HepatitisB ist u.a. auch in den USA, Europa und China gestellt.

🧬#Bepirovirsen marks a new milestone for chronic hepatitis B (#CHB).
GSK’s #ASO therapy Hibsago has become the first approved treatment for functional cure of CHB in Japan, opening new possibilities for #RNA-based therapeutics.

“The British drugmaker said bepirovirsen, to be branded as Hibsago, has been approved in Japan as ​the first and only functional cure for chronic hepatitis B ​in the country” www.reuters.com/business/hea...

#Japón ha aprobado #Hibsago de #GSK para la #hepatitisB crónica y #Orzeyful de #Takeda para la #narcolepsia tipo 1 www.ipharmacenter.com/post/japan-a...
#Japon #Noticias #Medios #Farma #Salud #Farmaceutica

#Japan has approved #GSK’s #Hibsago for chronic #hepatitisB and #Takeda’s #Orzeyful for #narcolepsy type 1
www.ipharmacenter.com/post/japan-a...
#Japan #News #Media #Pharma #Healthcare #Pharmaceutical

O #Japão aprovou o #Hibsago da #GSK para #hepatiteB crônica e o #Orzeyful da #Takeda para #narcolepsia tipo 1
www.ipharmacenter.com/post/japan-a...
#Japao #Noticias #Midia #Farma #Saude #Farmaceutica

Le #Japon a approuvé #Hibsago de #GSK pour l'#hépatiteB chronique et #Orzeyful de #Takeda pour la #narcolepsie de type 1 www.ipharmacenter.com/post/japan-a...
#Japon #Actualites #Medias #Pharma #Sante #Pharmaceutique

Il #Giappone ha approvato #Hibsago di #GSK per l'#epatiteB cronica e #Orzeyful di #Takeda per la #narcolessia di tipo 1
www.ipharmacenter.com/post/japan-a...
#Giappone #Notizie #Media #Pharma #Salute #Farmaceutica

🟢 #$GSK — Regulatory Approval
Japan MHLW Approval - First Global Approval, Functional Cure for Chronic Hepatitis B
Japan's Ministry of Health, Labour and Welfare (MHLW) approved Hibsago (bepirovirsen), an antisense oligonucleotide, as a functional cure for chron…

https://biostock.app/symbols/GSK

#GSK has announced that #Japan’s Ministry of Health, Labour and Welfare has approved Hibsago (#bepirovirsen), an #antisenseoligonucleotide, as a functional cure in #chronichepatitisB virus infection.

pharmaphorum.com/news/japan-f...

GSK wins first global approval for hepatitis B drug Hibsago